Altimmune Piotroski F Score

ALT
 Stock
  

USD 11.28  0.49  4.54%   

This module uses fundamental data of Altimmune to approximate its Piotroski F score. Altimmune F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Altimmune. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Altimmune financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please continue to Altimmune Altman Z Score, Altimmune Correlation, Altimmune Valuation, as well as analyze Altimmune Alpha and Beta and Altimmune Hype Analysis.
  
Altimmune Total Debt is comparatively stable at the moment as compared to the past year. Altimmune reported Total Debt of 64,436.4 in 2021. Debt Current is likely to gain to about 66.1 K in 2022, whereas Issuance Repayment of Debt Securities is likely to drop (269.7 K) in 2022. Altimmune Quick Ratio is comparatively stable at the moment as compared to the past year. Altimmune reported Quick Ratio of 10.31 in 2021. Asset Turnover is likely to gain to 0.0195 in 2022, whereas Cash Flow Per Share is likely to drop (1.96)  in 2022.
At this time, it appears that Altimmune's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeDecreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginNo ChangeFocus

Altimmune Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Altimmune is to make sure Altimmune is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Altimmune's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Altimmune's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted44.5 M41.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares44.5 M41.3 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(45.15)(41.8513)
Significantly Down
Increasing
Very volatile
Net Cash Flow from Operations(80.3 M)(78.2 M)
Fairly Down
Decreasing
Stable
Current Liabilities19.3 M18.3 M
Notably Up
Increasing
Very volatile
Total Liabilities21.7 M19.7 M
Significantly Up
Increasing
Very volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Total Debt66.1 K64.4 K
Fairly Up
Decreasing
Slightly volatile
Asset Turnover0.01950.019
Fairly Up
Decreasing
Slightly volatile
Current Assets220.2 M204.1 M
Significantly Up
Increasing
Slightly volatile
Total Assets236.1 M218.9 M
Significantly Up
Increasing
Slightly volatile

Altimmune F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Altimmune's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Altimmune in a much-optimized way.

About Altimmune Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

44.54 Million

Altimmune Weighted Average Shares is comparatively stable at the moment as compared to the past year. Altimmune reported Weighted Average Shares of 41.28 Million in 2021

Altimmune Current Valuation Drivers

We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.55 M)(1.45 M)(820.8 K)(1.14 M)(2.07 M)(2.12 M)
Revenue Per Employee357.94 K382.64 K232.06 K189.83 K93.84 K96.31 K
Average Assets62.24 M55.15 M59.45 M158.72 M244.32 M263.61 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(51.87 M)(45.03 M)(21.18 M)(54.52 M)(96.89 M)(99.44 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(51.76 M)(44.72 M)(20.19 M)(54.02 M)(96.53 M)(99.07 M)
Earnings before Tax(52.06 M)(45.32 M)(20.58 M)(54.46 M)(97.09 M)(99.65 M)
Average Equity45.56 M41.09 M52.61 M136.75 M224.03 M241.72 M
Enterprise Value14.64 M11.5 M18.09 M229.51 M189.11 M151.82 M
Free Cash Flow(20.37 M)(10.39 M)(9.6 M)(34.51 M)(90.36 M)(92.73 M)
Invested Capital8.21 M2.09 M28.41 M104.32 M(2.17 M)(2.22 M)
Invested Capital Average4.58 M3.32 M16.28 M54.88 M45.09 M48.65 M
Market Capitalization31.15 M18.04 M28.99 M373.04 M364.01 M392.74 M
Tangible Asset Value24.31 M40.9 M41.33 M232.29 M206.45 M222.74 M
Working Capital19.63 M34.84 M35.47 M218.24 M185.85 M200.52 M

About Altimmune Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Altimmune without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Pair Trading with Altimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Altimmune Altman Z Score, Altimmune Correlation, Altimmune Valuation, as well as analyze Altimmune Alpha and Beta and Altimmune Hype Analysis. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
554.5 M
Quarterly Revenue Growth YOY
(0.99) 
Return On Assets
(0.23) 
Return On Equity
(0.42) 
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.